Investigational drug · Phase 2
IRL757
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for PARKINSON DISEASE (Disorder), Apathy, Safety.
Phase 2Last checked: Nov 19, 2026Latest source record: Sep 3, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
3
Any phase or sponsor naming "IRL757"
First trial start
2026
Feb 18, 2026
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "IRL757", any sponsor or status.
Conditions studied
As listed on its trial records.
- PARKINSON DISEASE (Disorder)
- Apathy
- Safety
Approved drugs for the same conditions: Parkinson's disease · Neurology
Largest trials
Live from ClinicalTrials.gov: studies naming "IRL757" as an intervention, largest first.
Integrative Research Laboratories ABIndustry
NCT06493045 · 82 participants · Start May 16, 2024 · Primary completion Feb 7, 2025
Drug: IRL757; Placebo · For: Not Determined
Sites: Uppsala, Sweden
Integrative Research Laboratories ABIndustry
NCT07461220 · 75 participants (planned) · Start Feb 18, 2026 · Primary completion May 2027
Drug: IRL757; Placebo · For: PARKINSON DISEASE (Disorder); Apathy; Safety
Sites: Pleven, Bulgaria; Sofia, Bulgaria; Berlin, Germany · 14 sites in all
Integrative Research Laboratories ABIndustry
NCT06699628 · 12 participants · Start Sep 23, 2024 · Primary completion Nov 11, 2024
Drug: IRL757 · For: Not Applicable as This is a Mass Balance/Pharmacokinetic Study Performed in Healthy Subjects; Apathy
Sites: Uppsala, Sweden
Newest research
PubMed records naming it or its code names, newest first.
- Synthesis and pharmacological evaluation of a series of fluoro-substituted 3-phenoxy-azetidines as cortical enhancers for the treatment of apathy.
Sonesson C, von Unge S, Gullme M, et al. · Bioorg Med Chem Lett 2027
Also in development for PARKINSON DISEASE (Disorder)
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.